Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2009

01-02-2009 | Letter to the Editor

Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases

Authors: Giovanna De Vecchi, Paolo Verderio, Sara Pizzamiglio, Siranoush Manoukian, Monica Barile, Stefano Fortuzzi, Fernando Ravagnani, Marco A. Pierotti, Paolo Radice, Paolo Peterlongo

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Excerpt

To the Editor, …
Literature
1.
Sun T, Gao Y, Tan W et al (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39:605–613PubMedCrossRef
2.
Manoukian S, Peissel B, Pensotti V et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601–606PubMedCrossRef
3.
Hosmer Jr DW, Lemeshow S (1989) Applied logistic regression. John Wiley & Sons, New York
4.
Frank B, Rigas SH, Bermejo JL et al (2007) The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat. doi:10.​1007/​s10549-007-9752-z
5.
Cybulski C, Wokołorczyk D, Gliniewicz B et al (2007) A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat. doi:10.​1007/​s10549-007-9864-5
Metadata
Title
Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases
Authors
Giovanna De Vecchi
Paolo Verderio
Sara Pizzamiglio
Siranoush Manoukian
Monica Barile
Stefano Fortuzzi
Fernando Ravagnani
Marco A. Pierotti
Paolo Radice
Paolo Peterlongo
Publication date
01-02-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9963-y

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue

Clinical Trial

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy

Letter to the Editor

BRCA1 2080insA mutation in familial breast cancer

Brief Report

Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975–2001

Clinical Trial

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer

Preclinical Study

Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes

Review

Patho-biological aspects of basal-like breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits